Overall financial results Regional sales results Segment sales results Third-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 5.3%*, with net acquisitions and divestitures positively impacting growth by 1.6% due to CAPLYTA. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SP ...

Key Takeaways Q3 MedTech growth at J&J should have been driven by strength in Cardiovascular and Surgery.New products and acquired units, Abiomed and Shockwave, are expected to have fueled further sales momentum.VBP impacts in China might have restrained J&J's MedTech profit performance in Q3.Johnson & Johnson's (JNJ) medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J’s total revenues.I ...